MedPath
HSA Product

PANVAX® PANDEMIC INFLUENZA VACCINE (ADJUVANTED) 10ML SUSPENSION FOR INJECTION VIAL

Product approved by Health Sciences Authority (SG)

Basic Information

PANVAX® PANDEMIC INFLUENZA VACCINE (ADJUVANTED) 10ML SUSPENSION FOR INJECTION VIAL

INJECTION, SUSPENSION

Regulatory Information

SIN15801P

September 6, 2019

Prescription Only

Therapeutic

INTRAMUSCULAR

August 10, 2023

June 4, 2025

XJ07BB02

Company Information

Seqirus Pty Ltd

SEQIRUS PTE. LTD.

SEQIRUS PTE. LTD.

Active Ingredients

Detailed Information

Contraindications

**Contraindications** History of an anaphylactic (i.e. life-threatening) reaction to any of the constituents or trace residues (e.g. eggs, chicken protein refer to sections **Qualitative and Quantitative Composition** and **List of excipients** – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_) of this vaccine. However, in a pandemic situation, it may be appropriate to give the vaccine, provided that facilities for resuscitation are immediately available in case of need.

Indication Information

**Therapeutic indications** Prophylaxis of influenza in an officially declared pandemic situation. Pandemic influenza vaccine should be used in accordance with Singaporean Health Authorities’ recommendations, taking into account the recommendation of the World Health Organisation.

© Copyright 2025. All Rights Reserved by MedPath